hCD3EDG
Nomenclature
C57BL/6Smoc-Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Smoc
Cat. NO.
NM-HU-220120
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of human CD3E,CD3D,CD3G on T cell surface in HO hCD3EDG mice.
Fig.2 Lymphocyte Lineage Characterization in Blood in Homozygous hCD3EDG Mice.
Fig.3 In vivo AICD and irAE Assessment of Bispecific T Cell Engager Antibodies in Homzygous hCD3EDG Mice.
Homozygous hCD3EDG mice were engrafted with MC38-hEpCAM to evaluate the AICD and irAE of OKT3 and anti-CD3×EpCAM bispecific antibody in vivo.
Fig.4 In Vivo Response with Bispecific T Cell Engager Antibodies in Homozygous hCD3EDG Mice.
Homozygous hCD3EDG mice were engrafted with MC38-hCLDN18.2 to eveluate the in vivo efficacy of anti-CD3×Claudin18.2 bispecific antibody.
Fig.5 In vivo AICD and irAE Assessment of CD3 Bispecific Antibody in homozygous hCD3EDG Mice.
The anti-tumor response of anti-mPD-1 was evaluated in homozygous hCD3EDG mice bearing MC38 syngeneic tumor model.
Fig.6 In vivo AICD and irAE Assessment of CD3 Bispecific Antibody with Homozgyous hCD3EDG Mice.
Homozygous hCD3EDG mice were engrafted with MC38-hEpCAM to eveluate the AICD and irAE of anti-CD3×EpCAM bispecific antibody at low and high dose levels in vivo.
Fig.7 In Vivo Response with Bispecific T Cell Engager Antibodies.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more
